🇺🇸 FDA
Pipeline program

Rivaroxaban (Xarelto, BAY59-7939)

15786

Phase 3 small_molecule completed

Quick answer

Rivaroxaban (Xarelto, BAY59-7939) for Prevention & Control is a Phase 3 program (small_molecule) at Bayer HealthCare AG with 1 ClinicalTrials.gov record(s).

Program details

Company
Bayer HealthCare AG
Indication
Prevention & Control
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials